2024 Annual Results Forecast

SZSIJan 18 00:00 · Announcements

Express News | Jenkem Technology: It is expected that the net income in 2024 will decrease by 75.81% to 79.70% compared to the previous year.

BreakingsJan 17 17:33

Jenkem Technology (688356.SH): The company currently still does not plan to establish its own medical beauty sales team.

Gelonghui reported on December 24 that Jenkem Technology (688356.SH) stated on its investor interaction platform that regarding gel products, the company is purposefully making initial contacts with interested parties and has not yet formed a substantial agreement. The company currently does not plan to establish its own cosmetic sales team. For specific updates, please refer to the company's official disclosures.

Gelonghui FinanceDec 24, 2024 15:48

Express News | Next week, the unlocking ratio of 10 stocks will exceed 50%.

BreakingsNov 16, 2024 10:28

Jenkem Technology's Unit Completes Enrollment of First Subject for Polyethylene Glycol Irinotecan for Injection Trial

MT NewswiresNov 13, 2024 14:07

Jenkem technology (688356.SH): The first subject enrolled in the Phase II clinical trial of Polyethylene Glycol Ilibycin for the treatment of triple-negative breast cancer with brain metastases completed.

Gelonghui November 12th | Jenkem Technology (688356.SH) announced that its independently developed injection polyethylene glycol Iletikan (pharmaceutical code: JK1201I) for the treatment of triple-negative breast cancer with brain metastasis has completed the first subject enrollment in the phase II clinical trial "JK1201I treatment of triple-negative breast cancer with brain metastasis Phase II clinical study" recently.

Gelonghui FinanceNov 12, 2024 16:44